- XPOVIO ® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service (NHIS) for the treatment of adult patients with relapsed/refractory multiple myeloma (R/R MM). - The approval of XPOVIO ® by the NHIS in South Korea is the fourth national reimbursement in the Antengene markets after mainland of China , Australia and Singapore . - Additional reimbursements of XPOVIO ® in APAC markets are expected.
- Antengene has also submitted the new drug applications (NDAs) in additional ASEAN markets, including Thailand , Malaysia and Indonesia , where approvals are expected in the H2 of 2024. SHANGHAI and HONG KONG , June 26, 2024 /PRNewswire/ -- Antengene Corporation Limited (" Antengene ", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced that South Korea's National Health Insurance Service (NHIS) has approved the reimbursement of XPOVIO ® (selinexor) for the treatment of adult patients with relapsed or refractory multiple myeloma (R/R MM).
The drug is expected to be officially included into the national reimbursed drugs list on July 1, 2024 . MM, the second most common hematologic malignancy, is caused by the dysregulated proliferation of plasma cells. Patients with MM face a range of challenges including a high relapse rate, short survival, and limited treatment opt.
